ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q3 2023 Earnings Call Transcript

So looking ahead, given this early demand, we’re expanding our efforts beyond COE to reach physician to have fewer Rett patients, as well as family that aren’t as connected to clinicians or regularly visiting direct providers on a day-to-day basis.

Operator: Thank you. We have time for one more question which comes from the line of Jay Olson with Oppenheimer. You may proceed.

Jay Olson: Hey, congrats on the quarter and thank you for taking our questions. Based on the impressive DAYBUE launch dynamic so far, could you please share your latest thoughts on the longer term commercial potential in terms of what peak sales are achievable? And how does the commercial value of the ex-U.S. opportunity compared to the U.S. opportunity? Thank you.

Steve Davis: Thanks so much for the question, Jay. Mark, you want to take that?

Mark Schneyer: Yes, clearly. Jay, thanks for that. We’re very excited about what we have experienced in launch so far with DAYBUE. As we’ve said many times, we expect this to be a very, very meaningful product in terms of size. In the U.S., it could be similar to Pimavanserin just as a matter of and higher. But as a matter of kind of just our company policy and this we don’t put out at peak sales estimates; the size of the opportunity outside the U.S., there are more Rett patients just by population in Europe than there are in the U.S., little less in Japan than they are in U.S. The pricing dynamics in those markets could be a little different but we’re still working through that as we advance towards our regulatory efforts. So, more to come to discuss in the coming years.

Jay Olson: Thank you very much.

Operator: Thank you. This completes our question-and-answer session. Mr. Davis, please proceed to closing remarks.

Steve Davis: Great. Thanks so much, operator. Thanks again, everyone, for joining us today. We look forward to updating you on our progress next quarter.

Operator: Thank you, again, for your participation in today’s conference call. This concludes the presentation, and you may now disconnect. Good day.